REPCF - RepliCel Life Sciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1853
+0.0153 (+9.00%)
At close: 11:15AM EST
Stock chart is not supported by your current browser
Previous Close0.1700
Open0.1853
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1853 - 0.1853
52 Week Range0.1210 - 0.3570
Volume5,010
Avg. Volume8,976
Market Cap5.4M
Beta (5Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.0880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    RepliCel Provides 2019 Year-End Update

    RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders.

  • PR Newswire

    Clinical Data Published from RepliCel's Skin Rejuvenation Study

    VANCOUVER, Sept. 24, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce the publication of clinical data from its skin rejuvenation study (RCS-01) in an article entitled, Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study, published in the peer-reviewed journal Skin Pharmacology and Physiology (Skin Pharmacol Physiol http://dx.doi.org/10.1159/000502240). The publication summarizes data from a clinical trial in which it was shown that RepliCel's RCS-01 injections are well-tolerated for up to one-year post-injection and therefore safe to use.

  • PR Newswire

    RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China

    In a recent update to the RepliCel Board of Directors, the YOFOTO team reported that construction of its 4,700 sq metre facility dedicated to cell therapy manufacturing is now complete being commissioned for active production with capacity for clinical research manufacturing, material handling, purified water processing, research and development labs, QC/QA testing, cryopreservation storage, clinical biopsy/treatment space, and an exhibition hall.

  • PR Newswire

    RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector

    VANCOUVER, Aug. 29, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces it has retained the services of Damien King, an aesthetic dermatology product specialist and former executive in several top-tier companies, to help build out the global commercial strategy for the Company's automated dermal injector, RCI-02, and related consumables (the "RCI-02 Product Line").  RepliCel's RCI-02 Product Line is expected to market launch next year in Europe and Hong Kong after receiving CE marketing approval in the first half of 2020. Mr. King has more than 20 years of in-depth experience in the sales and marketing of pharmaceutical, biologic, and medical device products for some of the world's largest life science companies.

  • Reuters

    BRIEF-RepliCel Secures New Patents For Its Regenerative Medicine Technologies

    April 16 (Reuters) - Replicel Life Sciences Inc: * REPLICEL SECURES SEVERAL NEW PATENTS FOR ITS REGENERATIVE MEDICINE TECHNOLOGIES * REPLICEL LIFE SCIENCES-RECENTLY RECEIVED NOTIFICATIONS OF MANY PATENTS ...

  • PR Newswire

    RepliCel Secures Several New Patents for its Regenerative Medicine Technologies

    VANCOUVER, April 16, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has recently received notifications of several patents issued, allowed, and granted to the Company from Europe, China, Hong Kong, Japan, the United States and South Africa.

  • PR Newswire

    RepliCel's Licensee Building Momentum in China with Facility and Team

    VANCOUVER, March 26, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that its Licensee, YOFOTO (China) Health Co. ("YOFOTO"), headquartered in Ningbo, China, is rapidly building momentum on its licensed programs for Greater China, since closing the transaction with RepliCel in October last year.

  • PR Newswire

    RepliCel Reignites its First-in-Japan Strategy

    VANCOUVER, March 19, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce the resumption of their First-in-Japan strategy. The Company, working with industry leaders, CJ PARTNERS, have initiated a program in Japan to realize its goal of launching its cell therapy products in Japan sooner than would be possible anywhere else in the world. Because of this unique opportunity, the Company's next-phase trials will be conducted in Japan.

  • RepliCel CEO Provides 2019 Shareholder Update
    CNW Group

    RepliCel CEO Provides 2019 Shareholder Update

    VANCOUVER , March 5, 2019 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler . First, a quick recap of our Annual General Meeting held December 14, 2018 at which the shareholders elected a new slate of directors to RepliCel's Board - some re-elected, some new. The Board now has higher shareholder representation as well as a duly-elected nominee of our new investor/partner in Greater China .